AGT and chronic kidney disease: In view of the potential long‐lasting effects of silencing with N‐acetylgalactosamine‐siRNA conjugates treatment (such as with inclisiran, which is dosed every 6 months (Ray et al., 2017) targeting hepatic angiotensinogen offers new possibilities for the treatment of CKD in diabetic patients.